The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity

Nature Immunology

Volumn 1, Issue 6, 2000, Pages 469-474

  Siegel, Richard M ^a   Chan, Francis Ka Ming ^a   Chun, Hyung J ^a   Lenardo, Michael J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL MODEL; GENETICS; HOMEOSTASIS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; MOUSE; MUTATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD95; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CASPASES; FAS LIGAND PROTEIN; HOMEOSTASIS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MEMBRANE GLYCOPROTEINS; MICE; MODELS, BIOLOGICAL; MUTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0034574306     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/82712     Document Type: Review

References (115)

1. Yonehara, S., Ishii, A. & Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747-1756 (1989).
2. Trauth, B. C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305 (1989).
3. Kerr, J. F., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257 (1972).
4. Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243 (1991).
5. Naismith, J. H. & Sprang, S. R. Modularity in the TNF-receptor family. Trends Biochem. Sci. 23, 74-79 (1998).
6. Tartaglia, L A., Ayres, T. M., Wong, G. H. & Goeddel, D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74, 845-853 (1993).
7. Banner, D. W. et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 73, 431-445 (1993).
8. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
9. Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135 (1995).
10. Screaton, G. R. et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc. Natl Acad. Sci. USA 94, 4615-4619 (1997).
11. Chinnaiyan, A. M. et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990-992 (1996).
12. Kitson, J. et al. A death-domain-containing receptor that mediates apoptosis. Nature 384, 372-375 (1996).
13. Schneider, P. et al. Characterization of two receptors for TRAIL. FEBS Lett. 416, 329-334 (1997).
14. Schneider, P. et al. TRAIL receptors I (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κ. Immunity 7, 831-836 (1997).
15. Yen, W. C. et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279, 1954-1958 (1998).
16. Pan, G. et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818 (1997).
17. Walczak, H. et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386-5397 (1997).
18. Pan, G. et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 431, 351-356 (1998).
19. Golstein, P. Cell death: TRAIL and its receptors. Curr. Biol. 7, 750-753 (1997).
20. Marsters, S. A. et al. Identification of a ligand for the death-domain-containing receptor Apo3. Curr. Biol. 8, 525-528 (1998).
21. Pitti R. M. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699-703 (1998).
22. Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors . Science 277, 818-821 (1997).
23. Degli-Esposti, M. A. et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165-1170 (1997).
24. Marsters, S. A. et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003-1006 (1997).
25. Feldman, M., Taylor, P., Paleolog, E., Brennan, F. M. & Maini, R. N. Anti-TNF α therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc. 30, 4126-4127 (1998).
26. Kischkel, F. C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588 (1995).
27. Boldin, M. P. et al. A novel protein that interacts with the death domain of Fas-Apo-1 contains a sequence motif related to the death doman. J. Biol. Chem. 270, 7795-7798 (1995).
28. Chinnaiyan, A. M., O'Rourke, K., Tewari, M. & Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505-512 (1995).
29. Eberstadt, M. et al. NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature 392, 941-945 (1998).
30. Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827 (1996).
31. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V. & Wallach, D. Involvement of MACH, a novel MORTI/FADD-interacting protease. in Fas/APO-1- and TNF receptor-induced cell death. Cell 85, 803-815 (1995).
32. Nicholson, D. & Thornberry, N. Caspases: killer proteases. Trends Biochecm. Sci. 22, 299-306 (1997).
33. Martin, D. A. et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc. Natl Acad. Sci. USA 96, 4552-4557 (1999).
34. Yang, X., Chang, H. Y. & Baltimore, D. Autoproteolytic activation of pro-caspases by oligomerization. Mol. Cell 1, 319-325 (1998).
35. Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S. & Dixit, V. M. An induced proximity model for caspase-8 activation. J. Biol. Chem. 273, 2926-2930 (1998).
36. Martin, D. A., Siegel, R. M., Zheng, L. & Lenardo, M. J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal. J. Biol. Chem. 273, 4345-4349 (1998).
37. Zhang, J., Cado, D., Chen, A., Kabra, N. H. & Winoto, A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392, 296-300 (1998).
38. Varfolomeev, E. E. et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo 1, and DR3 and is lethal prenatally. Immunity 9, 267-276 (1998).
39. Scaffidi, C. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO. J. 17, 1675-1687 (1998).
40. Lenardo, M. J. et al. Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Int. Rev. Immunol. 13, 115-134 (1995).
41. Lenardo, M. et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol 17, 221-253 (1999).
42. Ju, S. T. et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444-448 (1995).
43. Dhein, J., Walczak, H., Baumler, C., Debatin, K. M. & Krammer, P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-441 (1995).
44. Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348-351 (1995).
45. Peter, M. E. et al. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol. 27, 1207-1212 (1997).
46. Refaeli, Y., Van Parijs, L., London, C. A., Tschopp, J. & Abbas, A. K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8, 615-623 (1998).
47. Scaffidi, C., Schmitz, I., Krammer, P. H. & Peter, M. E. The role of c-FUP in modulation of CD95-induced apoptosis. J. Biol. Chem 274, 1541-1548 (1999).
48. Russell, J. H., White, C. L., Loh, D. Y. & Meleedy-Rey, P. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc. Natl Acad. Sci. USA 88, 2151-2155 (1991).
49. Lenardo, M. J. Interleukin-2 programs mouse αβ lymphocytes for apoptosis. Nature 353, 858-861 (1991).
50. Wong, B., Arron, J. & Choi, Y. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J. Exp. Med. 186, 1939-1944 (1997).
51. Hornung, F., Zheng, L. & Lenardo, M. J. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of matureT lymphocytes. J. Immunol. 159, 3816-3822 (1997).
52. Combadiere, B. et al. Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis. J. Exp. Med. 183, 2109-2117 (1996).
53. Combadiere, B., e Sousa, C. R., Germain, R. N. & Lenardo, M. J. Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands. J. Exp. Med. 187, 349-355 (1998).
54. Sarin, A., Conan-Cibotti, M. & Henkart, P. A. Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts. J. Immunol. 155, 3716-3718 (1995).
55. Zhang, X. et al. Unequal death in T helper cell (Th)1 and Th2 effectors: ThI, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185, 1837-1849 (1997).
56. Varadhachary, A. S., Perdow, S. N., Hu, C., Ramanarayanan, M. & Salgame, P. Differential ability of T cell subsets to undergo activation-induced cell death. Proc. Natl Acad. Sci. USA 94, 5778-5783 (1997).
57. Boehme, S. A. & Lenardo, M. J. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23, 1552-1560 (1993).
58. Inaba, M. et al. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J. Immunol. 163, 1315-1320 (1999).
59. Desbarats, J., Wade, T., Wade, W. F. & Newell, M. K. Dichotomy between naive and memory CD4(+) T cell responses to Fas engagement. Proc. Natl Acad. Sci. USA 96, 8104-8109 (1999).
60. Van Parijs, L., Peterson, D. A. & Abbas, A. K. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 8, 265-274 (1998).
61. Kuroda, K. et al. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J. Immunol. 157, 1422-1431 (1996).
62. Goodnow, C. C. et al. Self-tolerance checkpoints in B lymphocyte development. Adv. Immunol. 59, 279-368 (1995).
63. Rathmell, J. C., Townsend, S. E., Xu, J. C., Flavell, R. A. & Goodnow, C. C. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87, 319-329 (1996).
64. Rothstein, T. L et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 374, 163-165 (1995).
65. Foote, L. C. et al. Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells. J. Immunol. 157, 1878-1885 (1996).
66. Wang, J. et al. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur. J. Immunol. 30, 155-163 (2000).
67. Gross J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-999 (2000).
68. Wu, Y. et al. Tumor Necrosis Factor Receptor Superfamily Member TAC1 is a High Affinity Receptor for TNF Family Members APRIL and BLyS. J. Biol. Chem. 275, 35478-35485 (2000).
69. Marsters, S. A. et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TAC1. Curr. Biol. 10, 785-783 (2000).
70. Xia, X. Z. et al. TAC1 is aTRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J. Exp. Med. 192, 137-143 (2000).
71. Thompson, J. S. et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med. 192, 129-135 (2000).
72. Kiener, P. A. et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J. Exp. Med 185, 1511-1516 (1997).
73. Kikuchi, H. et al. Monocytic differentiation modulates apoptotic response to cytotoxic anti-Fas antibody and tumor necrosis factor α in human monoblast U937 cells. J. Leukoc. Biol. 60, 778-783 (1996).
74. Perlman, H. et al. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J. Exp. Med. 190, 1679-1688 (1999).
75. Koppi, T. A., Tough-Bement, T., Lewinsohn, D. M., Lynch, D. H. & Alderson, M. R. CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. Eur. J. Immunol. 27, 3161-3165 (1997).
76. Ingulli, E., Mondino, A., Khoruts, A. & Jenkins, M. K. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J. Exp. Med. 185, 2133-2141 (1997).
77. Wang, J. et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98, 47-58 (1999).
78. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R. & Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
79. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
80. Restifo, N. P. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nature Med. 6, 493-495 (2000).
81. Zaks, T. Z., Chappell, D. B., Rosenberg, S. A. & Restifo, N. P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162, 3273-3279 (1999).
82. Wahlsten, J. L., Gitchell, H. L., Chan, C., Wiggert, B. & Caspi, R. R. Fas and FasL expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis. J. Immunol. 165, 5480-5486 (2000).
83. Chen, J. J., Sun, Y. & Nabel, G. J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717 (1998).
84. Kang, S. M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738-743 (1997).
85. Allison, J. Georgian, H. M., Strasser, A. & Vaux, D. L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl Acad. Sci. USA 94, 3943-3947 (1997).
86. Alderson, M. R. et al. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178, 2231-2235 (1993).
87. Kennedy, N. J., Kataoka, T., Tschopp, J. & Budd, R. C. Caspase activation is required for T cell proliferation. J. Exp. Med. 190, 1891-1896 (1999).
88. Alam, A., Cohen, L. Y., Aouad, S. & Sekaly, R. P. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 190, 1879-1890 (1999).
89. Kataoka, T. et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol. 10, 640-648 (2000).
90. Chu, J. L., Drappa, J., Parnassa, A. & Elkon, K. B. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J. Exp. Med. 178, 723-730 (1993).
91. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. & Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992).
92. Lynch, D. H. et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1, 131-136 (1994).
93. Fisher, G. H. et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946 (1995).
94. Rieux-Laucat, F. et al. Mutations in Fas-associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1351 (1995).
95. Straus, S. E., Sneller, M., Lenardo, M. J., Puck, J. M. & Strober, W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann. Intern. Med. 130, 591-601 (1999).
96. Sneller, M. C. et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J. Clin. Invest. 90, 334-341 (1992).
97. Sneller, M. C. et al. Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89, 1341-1348 (1997).
98. Cohen, P. L. & Eisenberg, R. A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9, 243-269 (1991).
99. Vidal, S., Kono, D. H. & Theofilopoulos, A. N. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J. Clin. Invest 101, 696-702 (1998).
100. Itoh, N. et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186, 613-618 (1997).
101. Kim, S. et al. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J. Immunol. 164, 2931-2936 (2000).
102. Su, X. et al. Significant role for Fas in the pathogenesis of autoimmune diabetes. J. Immunol. 164, 2523-2532 (2000).
103. Dittel, B. N., Merchant, R. M. & Janeway, C. A., Jr. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 162, 6392-6400 (1999).
104. Okuda, Y., Bernard, C. C., Fujimura, H., Yanagihara, T. & Sakoda, S. Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. Mol. Immunol. 35, 317-326 (1998).
105. Sabelko-Downes, K. A., Cross, A. H. & Russell, J. H. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189, 1195-1205 (1999).
106. Suvannavejh, G. C., Dal Canto, M. C., Maas, L. A. & Miller, S. D. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105, 223-231 (2000).
107. Critchfield, J. M. et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263, 1139-1143 (1994).
108. Jackson, C. et al. Autoimmune lymphoproliferative syndrome with defective Fas: Genotype influences penetrance. Am. J. Hum. Genet. 64, 1002-1014 (1998).
109. Vaishnaw, A. K. et al. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations J. Clin. Invest. 103, 355-363 (1999).
110. McWhirter, S. M. et al. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc. Natl Acad. Sci. USA 96, 8408-8413 (1999).
111. Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305-1308 (1998).
112. Wallach, D. et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331-367 (1999).
113. Chan, F. K. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354 (2000).
114. Siegel, R. M. et al. Fas preassociation, required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354-2357 (2000).
115. Papoff, G. et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J. Biol Chem. 274, 38241-38250 (1999).